Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Allergan discloses Phase II miss in LXR program

Paul Bonanos
January 11, 2017 5:32 PM UTC

Allergan plc (NYSE:AGN) said VTP-38543 did not show proof of concept in a Phase II trial to treat atopic dermatitis. Allergan acquired the liver X receptor beta (NR1H2; LXR-b) agonist via its $639 million purchase of Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) in a deal completed last week (see BioCentury Extra, Sept. 14).

During Allergan's 3Q16 earnings conference call Wednesday, Allergan Chief R&D Officer C. David Nicholson said that "target engagement was not satisfactorily achieved" in the study, and that the company intends to re-evaluate the concentration and formulation used...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Allergan plc

Vitae Pharmaceuticals Inc.